A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)

Torres et al., NCT04547127, NCT04547127, Feb 2021
200 patient convalescent plasma late treatment RCT with results not reported over 5 years after completion.
29 convalescent plasma RCTs have results missing long after expected1-29
The trials report a total of 3,534 patients, with 15 trials having actual enrollment of 1,143, and the remainder estimated.
Torres et al., 4 Feb 2021, Randomized Controlled Trial, Spain, trial NCT04547127 (history). Contact: mireia.torres@grifols.com, elsa.mondou@grifols.com.
Late treatment
is less effective